Skip to main content
An official website of the United States government
Grant Details

Grant Number: 5R01CA166559-05 Interpret this number
Primary Investigator: Landier, Wendy
Organization: University Of Alabama At Birmingham
Project Title: Quadrivalent Human Papillomavirus (HPV) Vaccine in Cancer Survivors
Fiscal Year: 2016


DESCRIPTION (provided by applicant): Advances in treatment for childhood cancer over the past five decades have resulted in a rapidly growing population of young cancer survivors, a substantial number of whom are adolescent/young adults - the age group at highest risk for sexually transmitted infection. Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States today, with prevalence in young, sexually active individuals ranging from 44.8% in females to 51.2% in males. Persistent infection with oncogenic strains of HPV (e.g., types 16 and 18) is associated with the development of cancers affecting the genital tract and oropharyngeal mucosa. Immunosuppression increases persistence of HPV infection and risk of HPV-related malignancies. Systemic cancer treatment may result in immunosuppression for prolonged periods, placing cancer survivors at higher risk for HPV-related morbidity. The quadrivalent HPV (qHPV) vaccine is indicated for prevention of HPV-related cancers and precancerous or dysplastic lesions in males and females between 9 and 26 years of age. The safety, tolerability, immunogenicity, and efficacy of the qHPV vaccine have been demonstrated in healthy young individuals; however, vaccine uptake to date has been low in the general population and no studies to date have determined vaccine uptake in cancer survivors, or the immunogenicity or safety/tolerability of the qHPV vaccine in this vulnerable population. Thus, there is a critical need to develop evidence to inform optimal uptake and utilization of the HPV vaccine in cancer survivors. This proposal aims to (1) estimate the prevalence of HPV vaccine initiation in cancer survivors 9-26 years of age and examine the sociodemographic, behavioral, and medical determinants of non-initiation; and (2) among non-immunized survivors, evaluate the 3-dose qHPV vaccine series to determine the following: Immunogenicity following the third and final vaccine dose; clinical/host factors influencing immunogenicity; and the safety/tolerability of the qHPV vaccine. Evaluation of the antibody response persistence at 1 and 2 years post-vaccine initiation and clinical/host factors influencing response persistence will be explored. If rates of HPV vaccine initiation are low among cancer survivors, this study will inform development of theory-based interventions to improve vaccine uptake, and identify subgroups likely to derive the most benefit from targeted interventions. This study will also identify clinical factors associated with inadequate immunogenic response to the vaccine and the impact of humoral competence on response, providing a foundation for future development of alternative vaccination strategies in subgroups unable to mount an adequate response to the standard 3-dose series. The proposed research addresses the high priority areas of health promotion, cancer prevention, and cancer survivorship. Importantly, males - a population that has been significantly understudied in regard to HPV vaccination - will be included; and the study will be conducted across four geographically distinct institutions to assure representation from an ethnically and racially diverse cohort of cancer survivors.


Reasons for refusal of the human papillomavirus vaccine among young cancer survivors.
Authors: Cherven B. , Klosky J.L. , Keith K.E. , Hudson M.M. , Bhatia S. , Landier W. .
Source: Cancer, 2023-02-15; 129(4), p. 614-623.
EPub date: 2022-12-19.
PMID: 36530157
Related Citations

Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial.
Authors: Landier W. , Bhatia S. , Wong F.L. , York J.M. , Flynn J.S. , Henneberg H.M. , Singh P. , Adams K. , Wasilewski-Masker K. , Cherven B. , et al. .
Source: The Lancet. Child & adolescent health, 2022 Jan; 6(1), p. 38-48.
EPub date: 2021-11-10.
PMID: 34767765
Related Citations

Sexual behaviors and human papillomavirus vaccine non-initiation among young adult cancer survivors.
Authors: Cherven B. , Klosky J.L. , Chen Y. , York J.M. , Heaton K. , Childs G. , Flynn J.S. , Connelly J.A. , Wasilewski-Masker K. , Robison L.L. , et al. .
Source: Journal of cancer survivorship : research and practice, 2021 Dec; 15(6), p. 942-950.
EPub date: 2021-02-06.
PMID: 33547560
Related Citations

Patient-Level Factors Associated With Lack of Health Care Provider Recommendation for the Human Papillomavirus Vaccine Among Young Cancer Survivors.
Authors: York J.M. , Klosky J.L. , Chen Y. , Connelly J.A. , Wasilewski-Masker K. , Giuliano A.R. , Robison L.L. , Wong F.L. , Hudson M.M. , Bhatia S. , et al. .
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020-09-01; 38(25), p. 2892-2901.
EPub date: 2020-06-18.
PMID: 32552278
Related Citations

Intent and subsequent initiation of human papillomavirus vaccine among young cancer survivors.
Authors: Cherven B. , Castellino S.M. , Chen Y. , Wong F.L. , York J.M. , Wasilewski-Masker K. , Hudson M.M. , Bhatia S. , Klosky J.L. , Landier W. .
Source: Cancer, 2019-11-01; 125(21), p. 3810-3817.
EPub date: 2019-07-10.
PMID: 31291010
Related Citations

Human Papillomavirus Vaccination Rates in Young Cancer Survivors.
Authors: Klosky J.L. , Hudson M.M. , Chen Y. , Connelly J.A. , Wasilewski-Masker K. , Sun C.L. , Francisco L. , Gustafson L. , Russell K.M. , Sabbatini G. , et al. .
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-11-01; 35(31), p. 3582-3590.
EPub date: 2017-08-24.
PMID: 28837404
Related Citations

Human Papillomavirus Vaccine Is Crucial for Adolescent and Young Adult Cancer Survivors.
Authors: Cherven B. , Landier W. .
Source: Journal of adolescent and young adult oncology, 2017 Sep; 6(3), p. 385-387.
EPub date: 2017-06-08.
PMID: 28595023
Related Citations

Back to Top